# reload+after+2024-01-23 05:36:13.977265
address1§Joukahaisenkatu 6 B
city§Turku
zip§20520
country§Finland
phone§358 2469 5151
fax§358 2469 5152
website§https://www.faron.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. It also develops Haematokine, an investigational AOC3 inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. In addition, the company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
fullTimeEmployees§40
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Juho Markku Jalkanen M.D., MSc, Ph.D.', 'age': 45, 'title': 'Chief Operating Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 546347, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Markku Tapani Jalkanen Ph.D.', 'age': 69, 'title': 'Founder, CEO & Executive Director', 'yearBorn': 1954, 'fiscalYear': 2022, 'totalPay': 241924, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': "Mr. James M. O'Brien CPA, M.B.A.", 'title': 'Chief Financial Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Maija  Hollmen Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Vesa  Karvonen L.L.M.', 'age': 51, 'title': 'General Counsel', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jennifer  Smith-Parker', 'title': 'Head of Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Juuso  Vakkuri M.A., M.B.A., M.Sc.', 'title': 'Chief Human Resources Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Juhana  Heinonen', 'title': 'Chief Commercial Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Birge  Berns M.D.', 'title': 'Interim Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§-0.073
currency§GBp
forwardEps§-0.23
exchange§LSE
quoteType§EQUITY
shortName§FARON PHARMACEUTICALS OY ORD NP
longName§Faron Pharmaceuticals Oy
firstTradeDateEpochUtc§1447747200
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§88bd39eb-ff29-3099-a793-70b5f621fa23
targetHighPrice§4.3
targetLowPrice§1.03
targetMeanPrice§2.75
targetMedianPrice§2.93
recommendationMean§2.8
recommendationKey§hold
numberOfAnalystOpinions§6
quickRatio§0.598
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
